Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.89 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.89 |
| ▸ | EGFR | P00533 | 8/20 | 0.89 |
| ▸ | WEE1 | P30291 | 6/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.75 |
| ▸ | ABL1 | P00519 | 7/20 | 0.75 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.74 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.74 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.74 |
| ▸ | KIT | P10721 | 3/20 | 0.74 |
| ▸ | STAT5A | P42229 | 1/20 | 0.69 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.69 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.69 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.68 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.68 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.68 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.68 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868353 | 0.94 | FGFR1 (1.00) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL25779595 | 0.92 | WEE1 (1.00) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL17520126 | 0.91 | SRC (0.90) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL10108142 | 0.89 | FGFR1 (0.87) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL5762046 | 0.86 | SRC (1.00) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL1249524 | 0.86 | FGFR1 (1.00) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL2083696 | 0.85 | SRC (1.00) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL5763306 | 0.85 | FGFR1 (1.00) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL5764062 | 0.85 | FGFR1 (1.00) | SRCFGFR1EGFRWEE1PDGFRB | |
| SCHEMBL4747103 | 0.83 | SRC (0.81) | SRCFGFR1EGFRWEE1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | SRC 176/4885FGFR1 115/4885EGFR 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.